STOCK TITAN

Autolus Therapeutics plc American Depositary Share - AUTL STOCK NEWS

Welcome to our dedicated page for Autolus Therapeutics plc American Depositary Share news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on Autolus Therapeutics plc American Depositary Share stock.

Autolus Therapeutics plc (NASDAQ: AUTL) is a pioneering biopharmaceutical company dedicated to the development and commercialization of engineered T-cell immunotherapy products. These innovative therapies are designed to treat life-threatening cancers with remarkable efficacy. Autolus is at the forefront of biotechnology, focusing on both haematological and solid tumors using patient-specific T-cell therapies.

At the heart of Autolus' clinical-stage pipeline is obecabtagene autoleucel (obe-cel). Additional promising candidates include AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8. These products represent the next generation of programmed T-cell therapies, offering new hope for cancer patients worldwide.

Autolus' strategic initiatives are equally impressive. The company has formed a strategic alliance with BioNTech SE, a key player in the biotech industry. This partnership is poised to enhance the development and reach of Autolus' therapies. Additionally, Autolus has successfully completed an underwritten offering, strengthening its financial foundation.

Recent financial results highlight the company's strong performance. For the full year ended December 31, 2023, Autolus reported unaudited financial results, including significant UK SME R&D Tax Credits. These credits amounted to $19.5 million and $24.6 million for the years ended December 31, 2023, and 2022, respectively, providing a substantial boost to their research and development efforts.

Looking ahead, Autolus has outlined key updates and anticipated milestones for obe-cel, along with financial results for the quarter ended March 31, 2024. These updates are critical for investors and stakeholders who are keen to track the company's progress and achievements.

In summary, Autolus Therapeutics plc is leading a transformative revolution in medicine, treating life-threatening diseases through cutting-edge T-cell therapies. The company's strategic partnerships, robust pipeline, and solid financials position it as a leader in the biopharmaceutical industry.

Rhea-AI Summary

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company focused on developing next-generation programmed T cell therapies, has announced its plans to release second quarter 2024 financial results and operational highlights. The release is scheduled for Thursday, August 8, 2024, before US markets open. Following the release, the company will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the financial results and provide a general business update. Interested participants are advised to pre-register for the conference call to receive dial-in numbers and a personal PIN. An audio webcast and replay will also be available on the events section of Autolus' website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
conferences earnings
-
Rhea-AI Summary

Autolus Therapeutics (Nasdaq: AUTL) will present three clinical updates on the therapy obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) at the European Hematology Association (EHA) Congress from June 13-16, 2024. Key data from the FELIX study indicate a 78% overall response rate (ORR) with median follow-up of 21.5 months, stabilizing long-term survival rates around 40%. Additional findings suggest the effectiveness of INO-containing bridging therapy and the sensitivity of ddPCR in monitoring CAR T persistence.

The median event-free survival (EFS) was 11.9 months and overall survival (OS) was 23.8 months, with 12-month EFS and OS rates at 49.5% and 61.1%, respectively. INO-containing therapies showed reduced bone marrow disease and minimized risks without increasing liver toxicity, while ddPCR proved more sensitive in monitoring CAR T-cell levels compared to flow cytometry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences clinical trial
-
Rhea-AI Summary

Autolus Therapeutics announced longer-term follow-up and additional data from the pivotal Phase 1b/2 FELIX study of obe-cel for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL). Presented at ASCO 2024, the data revealed that 40% of patients remain in remission without further therapy, showing potential long-term survival benefits. Median overall survival (OS) was 23.8 months, and median event-free survival (EFS) was 11.9 months. The FDA BLA submission has a target action date of November 16, 2024. The results support obe-cel as a standalone therapy with CAR T persistence linked to improved outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.01%
Tags
Rhea-AI Summary

Autolus Therapeutics (NASDAQ: AUTL) reported its Q1 2024 financial results, highlighting key developments and financial metrics. The company is progressing with its regulatory review processes for obe-cel in relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) with the FDA and European Medicines Agency (EMA). Key milestones include longer follow-up data from the FELIX Phase 2 trial, initial data from the CARLYSLE Phase 1 trial for Systemic Lupus Erythematosus (SLE) expected by late 2024, and the strategic CAR T cell therapy collaboration with BioNTech. Financially, the company reported cash and cash equivalents totaling $758.5 million as of March 31, 2024. Operating expenses were $38.8 million, with a net loss of $52.7 million for the quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.86%
Tags
-
Rhea-AI Summary

Autolus Therapeutics (Nasdaq: AUTL) announced the publication of three abstracts for the upcoming 2024 European Hematology Association (EHA) Congress, set for June 13-16, 2024. The studies focus on obecabtagene autoleucel (obe-cel) for treating relapsed/refractory B-Cell acute lymphoblastic leukemia. Key presentations include:

- An oral presentation by Dr. Claire Roddie on survival rates and CAR-T cell persistence in the FELIX study.

- A poster by Dr. Jae H. Park discussing the effects of inotuzumab-containing bridging therapy.

- Another poster by Dr. Claire Roddie on the sensitivity of droplet digital PCR and flow cytometry in measuring CAR-T cell kinetics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
conferences clinical trial
-
Rhea-AI Summary

Autolus Therapeutics plc, a biopharmaceutical company, has delayed its first quarter 2024 earnings release and conference call. The company will file a Form 12b-25 for an extension to file its Quarterly Report on Form 10-Q. The earnings release and call scheduled for May 14, 2024, are canceled, with the Q1 2024 10-Q expected to be filed by May 20, 2024. The conference call is rescheduled to May 17, 2024, for discussing financial results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
Rhea-AI Summary
Autolus Therapeutics plc announces the selection of the abstract for longer-term follow-up and additional data analysis from the pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL for an oral presentation at ASCO 2024. The presentation will cover overall survival, event-free survival, CAR-T cell persistency, and consolidative stem cell transplantation. Dr. Elias Jabbour will be the presenting author.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.03%
Tags
-
Rhea-AI Summary
Autolus Therapeutics plc (Nasdaq: AUTL) will announce its first quarter 2024 financial results and operational highlights on May 14, 2024. The company will host a conference call to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences earnings
-
Rhea-AI Summary
Autolus Therapeutics plc announces the acceptance of the Marketing Authorization Application (MAA) for obe-cel by the European Medicines Agency (EMA), based on data from the pivotal Phase 2 FELIX study in adult relapsed/refractory B-cell Acute Lymphoblastic Leukemia (ALL). The company's lead investigational CAR T cell therapy, obe-cel, has received various designations and certifications, including Orphan Drug Designation by the FDA and RMAT designation by the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
none
Rhea-AI Summary
Autolus Therapeutics plc (AUTL) appoints Mike Bonney as Chairman of the Board and Ravi Rao M.D. as Non-Executive Director, effective April 1, 2024. The company expresses gratitude to John H. Johnson for his leadership during key milestones. Mike Bonney brings extensive biotech and pharmaceutical experience, previously leading Cubist Pharmaceuticals, while Dr. Ravi Rao has a strong background in clinical development. These appointments signal Autolus' strategic focus on growth and expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.97%
Tags
management

FAQ

What is the current stock price of Autolus Therapeutics plc American Depositary Share (AUTL)?

The current stock price of Autolus Therapeutics plc American Depositary Share (AUTL) is $2.25 as of December 24, 2024.

What is the market cap of Autolus Therapeutics plc American Depositary Share (AUTL)?

The market cap of Autolus Therapeutics plc American Depositary Share (AUTL) is approximately 598.8M.

What does Autolus Therapeutics plc do?

Autolus Therapeutics plc develops and commercializes engineered T-cell immunotherapy products for treating life-threatening cancers.

What are the key products in Autolus' pipeline?

Key products include obecabtagene autoleucel (obe-cel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8.

Who are Autolus' strategic partners?

Autolus has a strategic alliance with BioNTech SE.

What are the financial highlights for Autolus?

For the year ended December 31, 2023, Autolus reported significant UK SME R&D Tax Credits of $19.5 million and $24.6 million in 2023 and 2022, respectively.

What recent milestones has Autolus achieved?

Recent milestones include strategic developments with BioNTech SE and the completion of an underwritten offering.

What are the anticipated milestones for obe-cel?

Autolus has outlined key updates and anticipated milestones for obe-cel, which are critical for tracking the company's progress.

What is the significance of Autolus' therapies?

Autolus' therapies offer extreme efficacy in treating life-threatening cancers, representing a significant advancement in cancer treatment.

How does Autolus' financial condition support its research?

Autolus' strong financial performance, bolstered by R&D Tax Credits, supports its robust research and development efforts.

Where is Autolus Therapeutics plc listed?

Autolus Therapeutics plc is listed on NASDAQ under the symbol AUTL.

What is the mission of Autolus Therapeutics plc?

Autolus aims to lead a revolution in medicine, treating life-threatening diseases with patient-specific T-cell therapies.

Autolus Therapeutics plc American Depositary Share

Nasdaq:AUTL

AUTL Rankings

AUTL Stock Data

598.77M
213.36M
18.09%
77.33%
2.35%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
LONDON